Dr. rer. nat. Sabrina Uhrig


Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year




Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041) (2023) Fasching P, Hein A, Kolberg HC, Häberle L, Uhrig S, Rübner M, Belleville E, et al. Journal article Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry (2022) Muller V, Hein A, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, et al. Journal article, Original article Return of individual genomic research results within the PRAEGNANT multicenter registry study (2022) Hübner H, Rübner M, Kurbacher C, Hadji P, Hartkopf AD, Lux MP, Huober J, et al. Journal article Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT (2022) Engler T, Fasching P, Lueftner D, Hartkopf AD, Mueller V, Kolberg HC, Hadji P, et al. Journal article Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis (2021) Fasching P, Yadav S, Hu C, Wunderle M, Häberle L, Hart SN, Rübner M, et al. Journal article Treatment landscape and prognosis after treatment with trastuzumab emtansine (2020) Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, et al. Journal article